Hazra, Saswati
Exelixis (United States)
4 papers on CoChat
Most cited papers
- Verified
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Kelley, R. K., Rimassa, L., Cheng, A.-L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., et al. (2022) · The Lancet Oncology
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 535
- Verified
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine
PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies
Cited by 332
- Verified
Peroxisome Proliferator-activated Receptor γ Induces a Phenotypic Switch from Activated to Quiescent Hepatic Stellate Cells
Hazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., & Tsukamoto, H. (2004) · Journal of Biological Chemistry
Liver physiology and pathologyPeroxisome Proliferator-Activated Receptors
Cited by 320
- Verified
PPAR Gamma and Hepatic Stellate Cells
Hazra, S., Miyahara, T., Rippe, R. A., & Tsukamoto, H. (2004) · Comparative Hepatology
Liver physiology and pathologyPeroxisome Proliferator-Activated Receptors
Cited by 66
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free